Innovative Addition to our CP Medical Veterinary Products
May 1, 2013 11:07 UTC
BUFORD, Ga.–(BUSINESS WIRE)–Theragenics Corporation® (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, today announced that CP Medical (a wholly-owned subsidiary of Theragenics) launched its “PLUS” line of antibacterial sutures for use in the veterinary market. The initial PLUS line includes the popular VISORB®, MONOSWIFT®, and MONO-DOX® sutures, now available with the antibacterial coating, chlorhexidine diacetate.
Chlorhexidine diacetate is an antibacterial agent that is effective against a variety of bacteria, including Staphylococcus aureus, Staphylococcus epidermidis, MRSA and MRSE. In suture, chlorhexidine greatly diminishes the ability of bacteria to colonize on the suture at the surgical site. The antibacterial coating does not change the feel, handling or performance of the sutures.
“Post-surgical infections of both humans and pets remain a significant concern to healthcare providers. Veterinary professionals are continually looking for products that improve the surgical outcomes of the animals in their care. This product line shows our commitment to providing veterinarians with innovative, niche products in growing markets. These types of products will continue to be a focus for us in the future,” said M. Christine Jacobs, Chairman and Chief Executive Officer of Theragenics Corporation.
MONO-DOX® PLUS is an antibacterial-coated polydioxanone synthetic absorbable, sterile, monofilament surgical suture. This suture features extended holding strength, excellent handling and has an FDA-approved dye for enhanced visibility during surgery. MONOSWIFT® PLUS is an antibacterial-coated, synthetic absorbable, sterile, monofilament surgical suture, composed of poly(glycolide-co-caprolactone) and features excellent holding strength, smooth tissue passage and superior handling. VISORB® PLUS is an antibacterial-coated, braided, synthetic absorbable surgical suture, composed of polyglycolic acid (PGA). It is available as both a dyed and undyed suture and features excellent tensile strength throughout the critical wound healing period. All products are available with or without needles.
CP Medical, along with NeedleTech Products and Galt Medical, comprise Theragenics’ surgical products business segment.
Theragenics Corporation(NYSE: TGX) operates two business segments: its surgical products business and its brachytherapy seed business. The surgical products business (www.cpmedical.com, www.galtmedical.com, www.needletech.com) manufactures and distributes wound closure, vascular access, and specialty needle products. Wound closure products include sutures, needles and other surgical products. Vascular access includes introducers, guidewires and related products. Specialty needles include coaxial, biopsy, spinal and disposable veress needles, access trocars, implanters, introducer products, and other needle-based products. The surgical products segment serves a number of markets and applications, including, among other areas, interventional cardiology, interventional radiology, vascular surgery, orthopedics, plastic surgery, dental surgery, urology, veterinary medicine, pain management, endoscopy, and spinal surgery. Theragenics’ brachytherapy business manufactures, custom loads, distributes and markets “seeds” used primarily in the minimally invasive treatment of localized prostate cancer. The Company’s brachytherapy product line (www.theragenicsbrachy.com) includes its palladium-103 TheraSeed® device and its iodine-125 AgX100® device. The terms “Company,” “we,” “us,” or “our” mean Theragenics Corporation and all entities included in our consolidated financial statements. For additional information, call our Investor Relations Department at (800) 998-8479 or visit www.theragenics.com.
Frank Tarallo, 800-998-8479 or 770-271-0233
CFO & Treasurer
Lisa Rassel, 800-998-8479 or 770-271-0233
Manager of Investor Relations